Cargando…

Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging

BACKGROUND: Antiangiogenic treatments have been shown to increase blood perfusion and oxygenation in some experimental tumors, and to reduce blood perfusion and induce hypoxia in others. The purpose of this preclinical study was to investigate the potential of dynamic contrast enhanced magnetic reso...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaustad, Jon-Vidar, Simonsen, Trude G., Smistad, Ragnhild, Wegner, Catherine S., Andersen, Lise Mari K., Rofstad, Einar K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647606/
https://www.ncbi.nlm.nih.gov/pubmed/26573613
http://dx.doi.org/10.1186/s12885-015-1918-1
_version_ 1782401136192389120
author Gaustad, Jon-Vidar
Simonsen, Trude G.
Smistad, Ragnhild
Wegner, Catherine S.
Andersen, Lise Mari K.
Rofstad, Einar K.
author_facet Gaustad, Jon-Vidar
Simonsen, Trude G.
Smistad, Ragnhild
Wegner, Catherine S.
Andersen, Lise Mari K.
Rofstad, Einar K.
author_sort Gaustad, Jon-Vidar
collection PubMed
description BACKGROUND: Antiangiogenic treatments have been shown to increase blood perfusion and oxygenation in some experimental tumors, and to reduce blood perfusion and induce hypoxia in others. The purpose of this preclinical study was to investigate the potential of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) and diffusion weighted MRI (DW-MRI) in assessing early effects of low dose bevacizumab treatment, and to investigate intratumor heterogeneity in this effect. METHODS: A-07 and R-18 human melanoma xenografts, showing high and low expression of VEGF-A, respectively, were used as tumor models. Untreated and bevacizumab-treated tumors were subjected to DCE-MRI and DW-MRI before treatment, and twice during a 7-days treatment period. Tumor images of K(trans) (the volume transfer constant of Gd-DOTA) and v(e) (the fractional distribution volume of Gd-DOTA) were produced by pharmacokinetic analysis of the DCE-MRI data, and tumor images of ADC (the apparent diffusion coefficient) were produced from DW-MRI data. RESULTS: Untreated A-07 tumors showed higher K(trans), v(e), and ADC values than untreated R-18 tumors. Untreated tumors showed radial heterogeneity in K(trans), i.e., K(trans) was low in central tumor regions and increased gradually towards the tumor periphery. After the treatment, bevacizumab-treated A-07 tumors showed lower K(trans) values than untreated A-07 tumors. Peripherial tumor regions showed substantial reductions in K(trans), whereas little or no effect was seen in central regions. Consequently, the treatment altered the radial heterogeneity in K(trans). In R-18 tumors, significant changes in K(trans) were not observed. Treatment induced changes in tumor size, v(e), and ADC were not seen in any of the tumor lines. CONCLUSIONS: Early effects of low dose bevacizumab treatment may be highly heterogeneous within tumors and can be detected with DCE-MRI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1918-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4647606
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46476062015-11-18 Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging Gaustad, Jon-Vidar Simonsen, Trude G. Smistad, Ragnhild Wegner, Catherine S. Andersen, Lise Mari K. Rofstad, Einar K. BMC Cancer Research Article BACKGROUND: Antiangiogenic treatments have been shown to increase blood perfusion and oxygenation in some experimental tumors, and to reduce blood perfusion and induce hypoxia in others. The purpose of this preclinical study was to investigate the potential of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) and diffusion weighted MRI (DW-MRI) in assessing early effects of low dose bevacizumab treatment, and to investigate intratumor heterogeneity in this effect. METHODS: A-07 and R-18 human melanoma xenografts, showing high and low expression of VEGF-A, respectively, were used as tumor models. Untreated and bevacizumab-treated tumors were subjected to DCE-MRI and DW-MRI before treatment, and twice during a 7-days treatment period. Tumor images of K(trans) (the volume transfer constant of Gd-DOTA) and v(e) (the fractional distribution volume of Gd-DOTA) were produced by pharmacokinetic analysis of the DCE-MRI data, and tumor images of ADC (the apparent diffusion coefficient) were produced from DW-MRI data. RESULTS: Untreated A-07 tumors showed higher K(trans), v(e), and ADC values than untreated R-18 tumors. Untreated tumors showed radial heterogeneity in K(trans), i.e., K(trans) was low in central tumor regions and increased gradually towards the tumor periphery. After the treatment, bevacizumab-treated A-07 tumors showed lower K(trans) values than untreated A-07 tumors. Peripherial tumor regions showed substantial reductions in K(trans), whereas little or no effect was seen in central regions. Consequently, the treatment altered the radial heterogeneity in K(trans). In R-18 tumors, significant changes in K(trans) were not observed. Treatment induced changes in tumor size, v(e), and ADC were not seen in any of the tumor lines. CONCLUSIONS: Early effects of low dose bevacizumab treatment may be highly heterogeneous within tumors and can be detected with DCE-MRI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1918-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-14 /pmc/articles/PMC4647606/ /pubmed/26573613 http://dx.doi.org/10.1186/s12885-015-1918-1 Text en © Gaustad et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Gaustad, Jon-Vidar
Simonsen, Trude G.
Smistad, Ragnhild
Wegner, Catherine S.
Andersen, Lise Mari K.
Rofstad, Einar K.
Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging
title Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging
title_full Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging
title_fullStr Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging
title_full_unstemmed Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging
title_short Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging
title_sort early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647606/
https://www.ncbi.nlm.nih.gov/pubmed/26573613
http://dx.doi.org/10.1186/s12885-015-1918-1
work_keys_str_mv AT gaustadjonvidar earlyeffectsoflowdosebevacizumabtreatmentassessedbymagneticresonanceimaging
AT simonsentrudeg earlyeffectsoflowdosebevacizumabtreatmentassessedbymagneticresonanceimaging
AT smistadragnhild earlyeffectsoflowdosebevacizumabtreatmentassessedbymagneticresonanceimaging
AT wegnercatherines earlyeffectsoflowdosebevacizumabtreatmentassessedbymagneticresonanceimaging
AT andersenlisemarik earlyeffectsoflowdosebevacizumabtreatmentassessedbymagneticresonanceimaging
AT rofstadeinark earlyeffectsoflowdosebevacizumabtreatmentassessedbymagneticresonanceimaging